Check out this presentation from PAREXEL Consulting experts to learn about key regulatory processes affecting biosimilars development including an an overview of the 351(k) Pathway, FDA approvals and managing post-approval challenges.
The document discusses Quality by Design (QbD) principles for pharmaceutical development and manufacturing. It defines key QbD concepts like critical quality attributes, critical process parameters, target product profiles, and control strategies. It provides an example of applying QbD through a risk assessment of a drug product manufacturing process to identify high risks and optimize the process to reduce failures and ensure consistent quality. The conclusions emphasize that QbD is an essential modern approach that links product quality to the manufacturing process through critical attributes and parameters.
The document discusses the International Council for Harmonization (ICH) and its goal of improving efficiency in drug development and registration. It provides an overview of the ICH's phases and agreement to continue harmonization efforts. The rest of the document focuses on Quality by Design (QbD), including defining the pharmaceutical development process, quality systems, quality risk management, and moving from empirical to systematic and knowledge-driven approaches. It provides details on the contents and topics that should be included in pharmaceutical development submissions to regulatory agencies.
This document discusses quality risk management principles and their application in product development. It defines key risk management terms and outlines a general quality risk management process involving risk identification, analysis, evaluation, control, and review. Various risk management tools are described that can be used at different stages of the product life cycle from development through commercialization. The document concludes with a case study showing how quality risk management was applied to identify critical inputs and processes for drug product quality attributes using exhibit batches.
The document discusses guidelines from the International Conference on Harmonization (ICH) related to quality and specifications of pharmaceutical products. It describes several ICH Q guidelines including Q1 on stability testing, Q2 on analytical method validation, Q3 on impurities, Q4 on pharmacopoeial harmonization, and Q5 on biotechnological/biological products. Key points covered include requirements for stability testing protocols, validation of analytical methods, identification and qualification of impurities, harmonization of pharmacopoeial standards, and viral safety evaluation of cell-derived biopharmaceuticals.
ICH Q6A Specifications by Chandra MohanChandra Mohan
The document provides guidelines on specifications for new drug substances and products. It defines specifications and outlines universal tests that should be included for both drug substances and products, such as description, identification, assay, and impurities. It also describes specific tests that may be included depending on the dosage form, such as dissolution, disintegration, hardness/friability for solid oral dosage forms. The guidelines provide information on justifying acceptance criteria and setting specifications based on development data and stability studies.
The document discusses guidelines for supplemental new drug applications (sNDAs) according to the US FDA. It outlines three categories of variations - major, moderate, and minor - based on their potential impact. Major changes require prior approval and could impact safety or efficacy. Moderate changes require submission 30 days before distribution or upon FDA receipt. Minor changes only require description in the annual report. The document provides examples of changes in manufacturing sites, processes, specifications, container closure systems, and labeling that would fall under each category. Close monitoring and reporting of any post-approval changes is recommended to ensure the quality, safety and efficacy of pre-qualified products are not adversely affected.
- Whilst the realization of the CTD took many years, there is now a common format for the submission of Marketing Authorizations Applications across the three ICH regions - Europe, Japan and the USA.
- This should facilitate pharmaceutical companies to make simultaneous filings in the ICH regions as it will eliminate the extensive work previously required to convert, for example, a US dossier to an EU dossier and vice versa.
The document discusses Quality by Design (QbD) principles for pharmaceutical development and manufacturing. It defines key QbD concepts like critical quality attributes, critical process parameters, target product profiles, and control strategies. It provides an example of applying QbD through a risk assessment of a drug product manufacturing process to identify high risks and optimize the process to reduce failures and ensure consistent quality. The conclusions emphasize that QbD is an essential modern approach that links product quality to the manufacturing process through critical attributes and parameters.
The document discusses the International Council for Harmonization (ICH) and its goal of improving efficiency in drug development and registration. It provides an overview of the ICH's phases and agreement to continue harmonization efforts. The rest of the document focuses on Quality by Design (QbD), including defining the pharmaceutical development process, quality systems, quality risk management, and moving from empirical to systematic and knowledge-driven approaches. It provides details on the contents and topics that should be included in pharmaceutical development submissions to regulatory agencies.
This document discusses quality risk management principles and their application in product development. It defines key risk management terms and outlines a general quality risk management process involving risk identification, analysis, evaluation, control, and review. Various risk management tools are described that can be used at different stages of the product life cycle from development through commercialization. The document concludes with a case study showing how quality risk management was applied to identify critical inputs and processes for drug product quality attributes using exhibit batches.
The document discusses guidelines from the International Conference on Harmonization (ICH) related to quality and specifications of pharmaceutical products. It describes several ICH Q guidelines including Q1 on stability testing, Q2 on analytical method validation, Q3 on impurities, Q4 on pharmacopoeial harmonization, and Q5 on biotechnological/biological products. Key points covered include requirements for stability testing protocols, validation of analytical methods, identification and qualification of impurities, harmonization of pharmacopoeial standards, and viral safety evaluation of cell-derived biopharmaceuticals.
ICH Q6A Specifications by Chandra MohanChandra Mohan
The document provides guidelines on specifications for new drug substances and products. It defines specifications and outlines universal tests that should be included for both drug substances and products, such as description, identification, assay, and impurities. It also describes specific tests that may be included depending on the dosage form, such as dissolution, disintegration, hardness/friability for solid oral dosage forms. The guidelines provide information on justifying acceptance criteria and setting specifications based on development data and stability studies.
The document discusses guidelines for supplemental new drug applications (sNDAs) according to the US FDA. It outlines three categories of variations - major, moderate, and minor - based on their potential impact. Major changes require prior approval and could impact safety or efficacy. Moderate changes require submission 30 days before distribution or upon FDA receipt. Minor changes only require description in the annual report. The document provides examples of changes in manufacturing sites, processes, specifications, container closure systems, and labeling that would fall under each category. Close monitoring and reporting of any post-approval changes is recommended to ensure the quality, safety and efficacy of pre-qualified products are not adversely affected.
- Whilst the realization of the CTD took many years, there is now a common format for the submission of Marketing Authorizations Applications across the three ICH regions - Europe, Japan and the USA.
- This should facilitate pharmaceutical companies to make simultaneous filings in the ICH regions as it will eliminate the extensive work previously required to convert, for example, a US dossier to an EU dossier and vice versa.
TSDP tells about Post-marketing Drug-surveillance and their types. To know more about regulatory medical writing training, contact- hello@turacoz.in. know more, visit: http://turacozskilldevelopment.org/
This presentation introduces Quality by Design (QbD) for pharmaceutical formulation and development. QbD requires understanding how formulation and process variables impact product quality to ensure predefined quality. The benefits of QbD include eliminating batch failures, minimizing deviations, and avoiding regulatory issues. For formulation and development, QbD involves establishing a quality target product profile, identifying critical quality attributes, conducting a risk assessment of drug substance and formulation attributes, developing an initial formulation, using design of experiments for optimization, establishing a control strategy, conducting pilot bioequivalence studies, and scale up with supporting stability studies.
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)ROHIT
This document presents an overview of ICH Q8 guidelines for pharmaceutical product development using Quality by Design (QbD) principles. It discusses key QbD concepts like Quality Target Product Profile, critical quality attributes, critical process parameters, and design space. The document also summarizes the contents that should be included in the CTD quality module regarding drug substances, formulation development, manufacturing process, container closure system, microbiological attributes, and compatibility studies. Finally, it emphasizes that QbD ensures quality is built into the product design rather than relying solely on end-product testing.
Concept of regulated and non regulated marketsHARSHITH58
This document discusses regulated and emerging pharmaceutical markets. It defines regulated markets as countries with stringent regulatory agencies like the FDA, EMA, and others. Emerging markets have less established regulatory frameworks. The document lists requirements and challenges for submitting drugs to regulated vs. emerging markets. It discusses the economic importance of each market type and calls for harmonization between requirements. Regulated markets are more profitable but emerging markets provide greater access to patients. India's domestic market is also outlined.
Quality control (QC) is a process by which entities review the quality of all factors involved in production. ISO 9000 defines quality control as "A part of quality management focused on fulfilling quality requirements In-process quality control tests are simply routine checks that are performed during production. They are those tests carried out before manufacturing process is completed to ensure that established product quality is met before they are approved for consumption and marketing.
The function of in-process quality control is monitoring and if necessary adaptation of the manufacturing processes to ensure that the product conforms to its specifications. This may include control of equipment and environment also.
This presentation is compiled by “ Drug Regulations” from freely available resources like the FDA on the World wide web. “Drug Regulations” is a non profit organization which provides free online resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest information from the world of Pharmaceuticals.
The document describes key concepts from ICH Q8 guidelines on pharmaceutical development, including defining a quality target product profile, identifying critical quality attributes, using risk assessment to link material and process attributes to critical quality attributes, establishing a design space, implementing a control strategy, and continually improving the product over its lifecycle. The guidelines provide a framework for a quality by design approach to pharmaceutical development and manufacturing.
This document summarizes the objectives and classification system of the Global Harmonization Task Force (GHTF) for in vitro diagnostic (IVD) medical devices. The GHTF was founded in 1993 to harmonize medical device regulations globally. It aims to facilitate trade while preserving public health. IVD medical devices are classified into 4 risk-based classes (A to D) based on 16 general rules related to device invasiveness, energy use, and disease detection. Class A devices pose the lowest risk while Class D the highest. The classification system aims to ensure regulatory oversight is proportionate to device risk.
The document discusses various guidelines issued by the US Food and Drug Administration (FDA) regarding products regulated by the FDA, such as foods, drugs, medical devices, biologics, cosmetics, and radiation emitting products. It also provides details on FDA guidelines for toxicological studies, clinical trials, manufacturing sterile products, MRI safety, transport temperature maintenance, and clinical trial phases. Guidelines are presented for topics like food packaging, color additives, and maintaining quality control and assurance in accordance with FDA standards.
The Code of Federal Regulations is the codification of rules and regulations issued by federal agencies in the United States. It is divided into 50 titles that are further divided into chapters and parts covering broad subject areas. New regulations are added daily and published in the Federal Register before being codified in the CFR. The CFR titles cover all areas of federal regulation including transportation, labor, agriculture, healthcare and more.
1) When filing an ANDA application, an applicant must provide information on any patents listed for the reference drug in the Orange Book.
2) In its application, a generic applicant must submit one of four certifications regarding the patents: that there are no patents (Paragraph I); any patents have expired (Paragraph II); any patents will expire on a specific date (Paragraph III); or the generic product does not infringe on or the patents are invalid (Paragraph IV).
3) A Paragraph I or II certification allows immediate approval, while a Paragraph III approval is effective after patent expiration. A Paragraph IV certification requires notifying the innovator and may allow early generic entry.
This document discusses vendor certification and categorization. It defines vendor certification as ensuring a vendor will meet regulatory expectations. Vendors are categorized from 1 to 4 based on risk, with category 1 being experts with minimal monitoring and category 4 being sole-source API manufacturers requiring intense monitoring. The document also outlines the vendor qualification process, including selection criteria, evaluation of production processes, and standard procedures for quality audits.
The document discusses the Abbreviated New Drug Application (ANDA) process for generic drugs. It provides background on the Hatch-Waxman Act of 1984 which established the ANDA pathway. The key points are:
1. The Hatch-Waxman Act aimed to balance innovation and access to medicines by providing incentives for brand and generic drug companies. It allowed generics to rely on brand safety data and established bioequivalence standards.
2. ANDAs contain data to demonstrate a generic drug is bioequivalent to the brand version. This allows generics to enter the market without duplicative clinical trials, lowering costs.
3. The FDA approves ANDAs if generics meet quality standards and their
This document provides guidelines for developing specifications for new drug substances and products according to ICH Q6A. It discusses universal and specific tests/criteria that should be included for drug substances and products, such as identification, description, assay, impurities, dissolution, disintegration, content uniformity, and microbial limits. The document gives acceptance criteria and justification for key tests like dissolution, discussing how to set Q values and limits based on biobatch results and BCS classification. It also provides guidance on other tests for oral liquids, parenterals and solid dosage forms.
The document discusses regulations for cosmetics in India according to the Drugs and Cosmetics Act of 1940 and Rules of 1945. It outlines the objectives of cosmetic regulations, definitions, requirements for importing and manufacturing cosmetics including licensing and labeling. Penalties are specified for offenses like importing spurious cosmetics or those containing harmful ingredients or misbranded products. Overall the document provides an overview of the regulatory framework and compliance requirements for the cosmetics industry in India.
This document provides an overview of ICH guidelines E9 through E12, which provide statistical and clinical trial design guidance. E9 discusses statistical principles for clinical trials, including trial context, scope, design techniques to avoid bias, sample size considerations, and data analysis. E10 covers choice of control groups in clinical trials and describes placebo, no treatment, dose-response, and active controls. E11 provides guidance for clinical trials in pediatric patients, including issues around timing, formulations, study types, age classifications, and ethical considerations. E12 relates to clinical evaluation by therapeutic category.
NDA and ANDA regulatory approval processJagrutiKale1
This document provides an overview of New Drug Applications (NDA) and Abbreviated New Drug Applications (ANDA). It discusses the requirements and process for submitting both full NDAs for new drugs and ANDAs for generic drugs. The key aspects covered are the format and content of NDA submissions, the review process by the FDA, and the different types of approval letters. It also explains the goals and requirements of the ANDA pathway for generic drugs established by the Hatch-Waxman Act, including the necessary patent certifications and the review process.
- The document presents information on the New Drug Application (NDA) process required by the FDA to obtain approval to market a new drug product in the United States.
- An NDA provides extensive data from non-clinical and clinical studies to establish the safety, efficacy, and appropriate labeling of the drug. It includes chemistry, manufacturing, and controls information as well as clinical data from Phase I-III trials.
- The goals of an NDA are to determine if the drug's benefits outweigh its risks, if its proposed labeling is appropriate, and if the methods used to manufacture and ensure the drug's quality are adequate.
Biosimilars are biopharmaceutical drugs that are similar to an existing approved biologic drug (the reference product). Biosimilars undergo a step-wise comparability exercise to demonstrate similarity in structure, function, safety and efficacy to the reference product. Regulatory agencies such as the FDA and EMA require extensive characterization, non-clinical and clinical studies to establish biosimilarity. Guidelines for approval of biosimilars have been established in regions such as Europe, US, Korea, Singapore and India to enable a pathway for approval of biosimilar versions of biologic drugs.
This document provides information on biosimilars and interchangeable biosimilars for health care providers. It defines key terms like reference product, biosimilar, and interchangeable. It describes the FDA approval pathways for biosimilars and generics. The FDA recommends a comparative analytical assessment and targeted clinical studies to demonstrate biosimilarity or interchangeability to a reference product. Clinical studies generally show biosimilars and interchangeable biosimilars are equivalent to their reference products in terms of safety, efficacy, and immunogenicity, including after switching. To date, the FDA has approved 4 interchangeable biosimilars.
TSDP tells about Post-marketing Drug-surveillance and their types. To know more about regulatory medical writing training, contact- hello@turacoz.in. know more, visit: http://turacozskilldevelopment.org/
This presentation introduces Quality by Design (QbD) for pharmaceutical formulation and development. QbD requires understanding how formulation and process variables impact product quality to ensure predefined quality. The benefits of QbD include eliminating batch failures, minimizing deviations, and avoiding regulatory issues. For formulation and development, QbD involves establishing a quality target product profile, identifying critical quality attributes, conducting a risk assessment of drug substance and formulation attributes, developing an initial formulation, using design of experiments for optimization, establishing a control strategy, conducting pilot bioequivalence studies, and scale up with supporting stability studies.
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)ROHIT
This document presents an overview of ICH Q8 guidelines for pharmaceutical product development using Quality by Design (QbD) principles. It discusses key QbD concepts like Quality Target Product Profile, critical quality attributes, critical process parameters, and design space. The document also summarizes the contents that should be included in the CTD quality module regarding drug substances, formulation development, manufacturing process, container closure system, microbiological attributes, and compatibility studies. Finally, it emphasizes that QbD ensures quality is built into the product design rather than relying solely on end-product testing.
Concept of regulated and non regulated marketsHARSHITH58
This document discusses regulated and emerging pharmaceutical markets. It defines regulated markets as countries with stringent regulatory agencies like the FDA, EMA, and others. Emerging markets have less established regulatory frameworks. The document lists requirements and challenges for submitting drugs to regulated vs. emerging markets. It discusses the economic importance of each market type and calls for harmonization between requirements. Regulated markets are more profitable but emerging markets provide greater access to patients. India's domestic market is also outlined.
Quality control (QC) is a process by which entities review the quality of all factors involved in production. ISO 9000 defines quality control as "A part of quality management focused on fulfilling quality requirements In-process quality control tests are simply routine checks that are performed during production. They are those tests carried out before manufacturing process is completed to ensure that established product quality is met before they are approved for consumption and marketing.
The function of in-process quality control is monitoring and if necessary adaptation of the manufacturing processes to ensure that the product conforms to its specifications. This may include control of equipment and environment also.
This presentation is compiled by “ Drug Regulations” from freely available resources like the FDA on the World wide web. “Drug Regulations” is a non profit organization which provides free online resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest information from the world of Pharmaceuticals.
The document describes key concepts from ICH Q8 guidelines on pharmaceutical development, including defining a quality target product profile, identifying critical quality attributes, using risk assessment to link material and process attributes to critical quality attributes, establishing a design space, implementing a control strategy, and continually improving the product over its lifecycle. The guidelines provide a framework for a quality by design approach to pharmaceutical development and manufacturing.
This document summarizes the objectives and classification system of the Global Harmonization Task Force (GHTF) for in vitro diagnostic (IVD) medical devices. The GHTF was founded in 1993 to harmonize medical device regulations globally. It aims to facilitate trade while preserving public health. IVD medical devices are classified into 4 risk-based classes (A to D) based on 16 general rules related to device invasiveness, energy use, and disease detection. Class A devices pose the lowest risk while Class D the highest. The classification system aims to ensure regulatory oversight is proportionate to device risk.
The document discusses various guidelines issued by the US Food and Drug Administration (FDA) regarding products regulated by the FDA, such as foods, drugs, medical devices, biologics, cosmetics, and radiation emitting products. It also provides details on FDA guidelines for toxicological studies, clinical trials, manufacturing sterile products, MRI safety, transport temperature maintenance, and clinical trial phases. Guidelines are presented for topics like food packaging, color additives, and maintaining quality control and assurance in accordance with FDA standards.
The Code of Federal Regulations is the codification of rules and regulations issued by federal agencies in the United States. It is divided into 50 titles that are further divided into chapters and parts covering broad subject areas. New regulations are added daily and published in the Federal Register before being codified in the CFR. The CFR titles cover all areas of federal regulation including transportation, labor, agriculture, healthcare and more.
1) When filing an ANDA application, an applicant must provide information on any patents listed for the reference drug in the Orange Book.
2) In its application, a generic applicant must submit one of four certifications regarding the patents: that there are no patents (Paragraph I); any patents have expired (Paragraph II); any patents will expire on a specific date (Paragraph III); or the generic product does not infringe on or the patents are invalid (Paragraph IV).
3) A Paragraph I or II certification allows immediate approval, while a Paragraph III approval is effective after patent expiration. A Paragraph IV certification requires notifying the innovator and may allow early generic entry.
This document discusses vendor certification and categorization. It defines vendor certification as ensuring a vendor will meet regulatory expectations. Vendors are categorized from 1 to 4 based on risk, with category 1 being experts with minimal monitoring and category 4 being sole-source API manufacturers requiring intense monitoring. The document also outlines the vendor qualification process, including selection criteria, evaluation of production processes, and standard procedures for quality audits.
The document discusses the Abbreviated New Drug Application (ANDA) process for generic drugs. It provides background on the Hatch-Waxman Act of 1984 which established the ANDA pathway. The key points are:
1. The Hatch-Waxman Act aimed to balance innovation and access to medicines by providing incentives for brand and generic drug companies. It allowed generics to rely on brand safety data and established bioequivalence standards.
2. ANDAs contain data to demonstrate a generic drug is bioequivalent to the brand version. This allows generics to enter the market without duplicative clinical trials, lowering costs.
3. The FDA approves ANDAs if generics meet quality standards and their
This document provides guidelines for developing specifications for new drug substances and products according to ICH Q6A. It discusses universal and specific tests/criteria that should be included for drug substances and products, such as identification, description, assay, impurities, dissolution, disintegration, content uniformity, and microbial limits. The document gives acceptance criteria and justification for key tests like dissolution, discussing how to set Q values and limits based on biobatch results and BCS classification. It also provides guidance on other tests for oral liquids, parenterals and solid dosage forms.
The document discusses regulations for cosmetics in India according to the Drugs and Cosmetics Act of 1940 and Rules of 1945. It outlines the objectives of cosmetic regulations, definitions, requirements for importing and manufacturing cosmetics including licensing and labeling. Penalties are specified for offenses like importing spurious cosmetics or those containing harmful ingredients or misbranded products. Overall the document provides an overview of the regulatory framework and compliance requirements for the cosmetics industry in India.
This document provides an overview of ICH guidelines E9 through E12, which provide statistical and clinical trial design guidance. E9 discusses statistical principles for clinical trials, including trial context, scope, design techniques to avoid bias, sample size considerations, and data analysis. E10 covers choice of control groups in clinical trials and describes placebo, no treatment, dose-response, and active controls. E11 provides guidance for clinical trials in pediatric patients, including issues around timing, formulations, study types, age classifications, and ethical considerations. E12 relates to clinical evaluation by therapeutic category.
NDA and ANDA regulatory approval processJagrutiKale1
This document provides an overview of New Drug Applications (NDA) and Abbreviated New Drug Applications (ANDA). It discusses the requirements and process for submitting both full NDAs for new drugs and ANDAs for generic drugs. The key aspects covered are the format and content of NDA submissions, the review process by the FDA, and the different types of approval letters. It also explains the goals and requirements of the ANDA pathway for generic drugs established by the Hatch-Waxman Act, including the necessary patent certifications and the review process.
- The document presents information on the New Drug Application (NDA) process required by the FDA to obtain approval to market a new drug product in the United States.
- An NDA provides extensive data from non-clinical and clinical studies to establish the safety, efficacy, and appropriate labeling of the drug. It includes chemistry, manufacturing, and controls information as well as clinical data from Phase I-III trials.
- The goals of an NDA are to determine if the drug's benefits outweigh its risks, if its proposed labeling is appropriate, and if the methods used to manufacture and ensure the drug's quality are adequate.
Biosimilars are biopharmaceutical drugs that are similar to an existing approved biologic drug (the reference product). Biosimilars undergo a step-wise comparability exercise to demonstrate similarity in structure, function, safety and efficacy to the reference product. Regulatory agencies such as the FDA and EMA require extensive characterization, non-clinical and clinical studies to establish biosimilarity. Guidelines for approval of biosimilars have been established in regions such as Europe, US, Korea, Singapore and India to enable a pathway for approval of biosimilar versions of biologic drugs.
This document provides information on biosimilars and interchangeable biosimilars for health care providers. It defines key terms like reference product, biosimilar, and interchangeable. It describes the FDA approval pathways for biosimilars and generics. The FDA recommends a comparative analytical assessment and targeted clinical studies to demonstrate biosimilarity or interchangeability to a reference product. Clinical studies generally show biosimilars and interchangeable biosimilars are equivalent to their reference products in terms of safety, efficacy, and immunogenicity, including after switching. To date, the FDA has approved 4 interchangeable biosimilars.
Presentation about Biosimilars on Save Your Skin Foundation webinar, January 19, 2018. This is presentation #1 of 3 in the webinar: 1. Health Canada 2. CADTH 3. Louise Binder, Save Your Skin Fdn.
The document discusses regulatory requirements for bioequivalence studies from the FDA and WHO perspectives. It defines key terms like bioavailability, bioequivalence, reference product and generic products. It also outlines FDA guidelines on bioequivalence documentation for INDs, NDAs and ANDAs. Test procedures for establishing bioequivalence include pharmacokinetic, pharmacodynamic and clinical studies according to FDA regulations. Pharmacokinetic studies are emphasized for directly measuring drug absorption. Study design considerations like single vs multiple dose studies are also covered.
Biosimilars: Regulatory and Clinical ConsiderationsCovance
Other considerations for clinical studies are that the regulations are written with some flexibility, and although clinical studies have been required thus far, they are not mandated by the regulations. Perception from sponsors is that innovators make process changes all the time that impact structure and no clinical study is done because of good analytical characterization so why are biosimilars different? With solid analytical and functional data, we should continue to challenge regulators on the need for clinical studies.
IPhVC recommendations & monitoring requirement of biosimilars, Worldwide & Iraq control of Bioproducts & biosimiliars, as well as references enlisted adverse reactions to common products used in our hospital
Lecture presented at the 31st Jan 2024 in our hospital
The document discusses biosimilars and the regulatory pathway for biosimilar approval in India. It provides background on biosimilars and how they differ from generics in terms of manufacturing complexity and clinical development requirements. It summarizes India's draft biosimilar guidelines, including that phase III trials with 100+ patients are required for approval but phase I-II may be waived. The guidelines aim to streamline the process while aligning with global standards from the EMA and WHO. Over 20 biosimilars have been approved in India across several therapeutic classes.
Biologicals and biosimilars are complex drugs produced by living cells. Biosimilars are similar but not identical copies of biological reference drugs. Regulatory requirements for biosimilars are more extensive than generics but less so than original biological drugs. Biosimilars require comparative quality analysis, limited clinical trials and toxicity studies against the reference drug. Due to inherent structural differences, biosimilars cannot be considered interchangeable with the reference drug.
This document summarizes a view from the biosimilar industry on implementing the WHO guidelines for evaluating biosimilar products. It makes three key points:
1) The WHO guidelines provide important global harmonization and clear guidance for regulators and industry on developing biosimilars. They confirm the principles of biosimilarity used in other regional guidelines.
2) Developing biosimilars requires a standalone manufacturing process and demonstrating comparability through extensive quality, preclinical, and clinical testing, including a comparative Phase III study. This development strategy is different than for generic drugs.
3) Experience from manufacturing changes for originator products can be applied to biosimilar development and approval according to the WHO guidelines. This
The document summarizes the key principles of the WHO guidelines on evaluating biosimilar products. It states that the WHO guidelines represent an important step in harmonizing global regulation of biosimilars and provide clear guidance for regulators and industry. The guidelines confirm that biosimilars must be developed through a stand-alone manufacturing process that demonstrates comparability to the reference product. Experience from evaluating manufacturing changes to originator products can be applied to developing and approving biosimilars according to the WHO guidelines.
This document discusses biosimilar drugs. It begins by explaining that biosimilars are biologic medications that are highly similar to but not exact copies of an original biologic. It then discusses regulatory concerns around biosimilar development and approval including ensuring safety and effectiveness given potential immunogenicity issues. The document provides an overview of some biosimilars currently approved in other countries and areas of concern regarding biosimilar use such as interchangeability, pharmacovigilance, and naming.
There has been a parallel advancement in the field of biosimilars with other recent biologic medications like cell line science and protein expression science. These are molecules that are chemically similar to their already approved biological medication counterparts which enable a faster and more cost-effective production as they only require one clinical trial, unlike the reference product which has to usually undergo two. Recently, various biosimilars for ophthalmic use have been developed and studied in various parts of the world.
This document summarizes information about biosimilars and the regulatory pathways for their approval in the United States and European Union. It discusses how biosimilars differ from traditional small-molecule generics due to biological molecules' larger size, greater complexity, and manufacturing dependence. The U.S. passed the Biologics Price Competition and Innovation Act in 2010 to create an approval pathway for follow-on biologics, requiring biosimilarity demonstration and possible interchangeability labeling. Upcoming FDA hearings will provide information to guide biosimilar approval requirements regarding analytical and clinical data needs. The E.U. has approved several biosimilars under its regulatory framework established in 2005.
Biosimilaridad e intercambiabilidad: principios y evidencia: una revisión sis...Rosmirella Cano Rojas
Existen importantes lagunas en la evidencia sobre la seguridad de cambiar entre productos biológicos y sus biosimilares. Se necesitan ensayos clínicos y de farmacovigilancia suficientemente potenciados y adecuadamente analizados estadísticamente , con seguimientos a largo plazo y múltiples cambios, para respaldar la toma de decisiones sobre el cambio biosimilar.
“Principles of a Science-Based Regulatory Pathway for Biosimilar Products”
Provides an overview of the guiding principles for a science-based regulatory pathway for biosimilar products
The document discusses generic drugs and biosimilars. It provides biographical information about the speaker and outlines key questions about generics that will be addressed. Generic drugs are defined as comparable but not identical to brand name drugs in dosage, strength, quality and performance. Biosimilars are similar to biologic drugs but require more extensive testing than generics due to their complex nature. The market for generic drugs is large and growing, particularly in emerging markets, as major drugs lose patent protection.
Hope S. Rugo, MD, FASCO, prepared useful Practice Aids pertaining to biosimilars for this CME/MOC/CNE/CPE activity titled "Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Care." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at http://bit.ly/38DBgFb. CME/MOC/CNE/CPE credit will be available until April 27, 2021.
This document provides an overview of biosimilars including their definition, categories, development principles, and regulatory approval process. Biosimilars are biological products that are highly similar to an existing approved biologic reference product. They are developed through a stepwise comparative process to demonstrate similarity in terms of safety, purity and potency. Some key points covered include:
- Biosimilars are large protein therapeutics derived from living organisms unlike traditional small molecule drugs.
- They include categories like hormones, monoclonal antibodies, and recombinant proteins.
- Their development follows principles of extensive characterization studies comparing them to the reference product.
- In India, biosimilars require approval through the regulatory pathway overseen by authorities
The document discusses biosimilar biological products and the FDA's guidance on them. The FDA has established an abbreviated licensure pathway for biosimilar biological products shown to be biosimilar to an FDA-licensed reference product. A biosimilar application must include analytical, animal, and clinical studies demonstrating biosimilarity based on being highly similar to the reference product with no clinically meaningful differences in safety, purity, and potency. The FDA evaluates all the evidence submitted using a totality of evidence approach.
Improving Processes for Temperature Traceability from Packaging to PatientPAREXEL International
Check out this presentation from PAREXEL Randomization and Trial Supply Experts to learn about temperature monitoring practices throughout the clinical trial supply chain, including: traditional temperature monitoring methods, innovative methods and how to apply the best approach to individual studies.
The document discusses strategies for successful global drug development. It focuses on navigating FDA accelerated approval programs, new frontiers in personalized medicine, and evolving regulatory paradigms for digital health. The presentation provides an overview of key FDA expedited programs like fast track designation and breakthrough therapy designation. It also examines how regulators are adapting approaches to personalized medicine and digital health technologies.
PAREXEL Early Phase Clinical Research Services experts discuss developing trends in drug development including adaptive trials design, real-world data and biomarkers.
Understanding Regulatory and Payer Requirements Throughout CommercializationPAREXEL International
Learn about regulator and payer evidence requirements as well as other key market access considerations in drug development. Read this presentation from PAREXEL Consulting experts.
Innovative Pricing and Reimbursement Schemes - The Why, What, Which & HowPAREXEL International
Learn about the need for innovation in global reimbursement mechanisms, the potential risks and benefits of implementation, and real world examples in a presentation by PAREXEL Access Consulting Experts.
Leveraging Imaging and Wearable Technology For Agile Clinical TrialsPAREXEL International
Learn how to manage and overcome key challenges to deploying imaging and wearable technology effectively in clinical trials from PAREXEL Consulting experts.
Understanding Different Stakeholder Requirements Throughout CommercializationPAREXEL International
The document discusses the emerging gap between the evidence required by regulators for drug approval and payers for reimbursement. Regulators are approving new therapies like gene and CAR-T cell therapies based on early phase clinical trial data through expedited pathways. However, payers increasingly demand real-world evidence of comparative effectiveness and economic value. The use of real-world evidence is presented as a way to bridge this gap by providing additional evidence on benefits, safety, and cost-effectiveness to optimize market success and reimbursement.
This document discusses the synergies between regulatory information management (RIM) and identification of medicinal products (IDMP). It argues that RIM and IDMP should be considered together, not separately, as IDMP expands on product data beyond what was traditionally included in RIM. The implementation of IDMP standards will converge various regulatory data initiatives and shape future regulatory submissions that will utilize structured IDMP data instead of documents. RIM systems will benefit from using the IDMP data model to standardize product information captured across systems and sources.
This document provides tips for productive FDA meetings. It advises understanding FDA's perspectives and being flexible in discussions. While FDA aims to innovate, sponsors need to show how their approaches address current needs. Agreement is not always the goal; it is better sometimes to get FDA to tolerate an approach. Meeting minutes may lack clarity, so sponsors should summarize discussion points. Experts and patients at meetings can provide value if well-prepared.
PAREXEL Principal Consultant Angela McGillivary discusses commercial considerations, clinical development, regulatory requirements, submission and post approval strategies in emerging markets
Aligning on Patient Outcomes - How Market Dynamics Can Facilitate RWD SolutionsPAREXEL International
This document discusses how real-world data can be used to better understand patient outcomes. It notes that legislation, technology advances, and a shift toward valuing outcomes over volume are accelerating the focus on using real-world data to determine what treatment approaches improve patient outcomes. The document outlines challenges to using real-world data like data quality issues and privacy concerns, and proposes strategies like using hybrid study designs that combine electronic medical record data with traditional clinical trial data collection to help overcome these challenges. Finally, it emphasizes that solutions in this area will need to be developed incrementally while protecting patient privacy and gaining regulatory acceptance.
You're Hot Then You're Cold - Temperature Management & RTSM IntegrationPAREXEL International
The document discusses innovative temperature monitoring solutions for clinical trial supply chains. It presents two approaches: near real-time temperature monitoring and in-pack Bluetooth enabled monitoring. The near real-time approach uses loggers in shipments that upload data to automatically analyze material status. The in-pack approach uses loggers placed in medication packs that remain with the pack and can be scanned via Bluetooth. Two case studies apply the solutions: near real-time is best for a personalized medicine study, while in-pack fits a 9-month vaccine study due to long battery life and final dispensation check. Innovative temperature monitoring can streamline processes while ensuring drug safety and quality.
Drug manufacturers are looking to emerging markets like Latin America to fuel long-term success.
View this PAREXEL Consulting presentation to learn more.
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...Neil Horowitz
On episode 272 of the Digital and Social Media Sports Podcast, Neil chatted with Brian Fitzsimmons, Director of Licensing and Business Development for Barstool Sports.
What follows is a collection of snippets from the podcast. To hear the full interview and more, check out the podcast on all podcast platforms and at www.dsmsports.net
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
Part 2 Deep Dive: Navigating the 2024 Slowdownjeffkluth1
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
Easily Verify Compliance and Security with Binance KYCAny kyc Account
Use our simple KYC verification guide to make sure your Binance account is safe and compliant. Discover the fundamentals, appreciate the significance of KYC, and trade on one of the biggest cryptocurrency exchanges with confidence.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
Best practices for project execution and deliveryCLIVE MINCHIN
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...my Pandit
Dive into the steadfast world of the Taurus Zodiac Sign. Discover the grounded, stable, and logical nature of Taurus individuals, and explore their key personality traits, important dates, and horoscope insights. Learn how the determination and patience of the Taurus sign make them the rock-steady achievers and anchors of the zodiac.
Digital Marketing with a Focus on Sustainabilitysssourabhsharma
Digital Marketing best practices including influencer marketing, content creators, and omnichannel marketing for Sustainable Brands at the Sustainable Cosmetics Summit 2024 in New York
How to Implement a Real Estate CRM SoftwareSalesTown
To implement a CRM for real estate, set clear goals, choose a CRM with key real estate features, and customize it to your needs. Migrate your data, train your team, and use automation to save time. Monitor performance, ensure data security, and use the CRM to enhance marketing. Regularly check its effectiveness to improve your business.
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....Lacey Max
“After being the most listed dog breed in the United States for 31
years in a row, the Labrador Retriever has dropped to second place
in the American Kennel Club's annual survey of the country's most
popular canines. The French Bulldog is the new top dog in the
United States as of 2022. The stylish puppy has ascended the
rankings in rapid time despite having health concerns and limited
color choices.”
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...APCO
The Radar reflects input from APCO’s teams located around the world. It distils a host of interconnected events and trends into insights to inform operational and strategic decisions. Issues covered in this edition include:
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
1. Scott, B. et al., “Biosimilar Monoclonal Antibodies: A Canadian Regulatory Perspective on the Assessment of Clinically Relevant Differences and Indication Extrapolation.” J Clin Pharmacol. 2015 Mar;55 Suppl 3:S123-32.
2. European Medicines Agency, Draft Guideline on Immunogenicity assessment of 6 biotechnology-derived therapeutic proteins, 24 September 2015, 1 EMEA/CHMP/BMWP/14327/2006 Rev. 1.
3. FDA, Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products (August 2014).
4. PMDA, Guidelines for the Quality, Safety and Efficacy Assurance of Follow-on Biologics,” English Translation (PFSB/ELD No.0304007) by PhRMA.
5. World Health Organization, Guidelines of Evaluation of Similar Biotherapeutic Products (SBPs) (2009).
1. Ireland Health Products Regulatory Agency, Guide to Biosimilars for Healthcare Professionals and Patients, 14 October 2015.
2. MHRA, Drug Safety Update: Biosimilar products (February 2008), https://www.gov.uk/drug-safety-update/biosimilar-products.
3. Paul Ehrlich Institute's position on the interchangeability of biosimilars.